Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05629598
Other study ID # CRAD-006-02
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 13, 2022
Est. completion date August 16, 2023

Study information

Verified date November 2022
Source Angde Biotech Pharmaceutical Co., Ltd.
Contact Jianghua Chen, Master
Phone 0571-87236996
Email zyct79@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to explore the optimal dose and administration of the experimental drug, and to evaluate the safety and efficacy of the drug in patients with renal anemia. Patients with renal anemia on regular dialysis treatment are expected to be enrolled in this study.


Description:

This study is a multi-center, randomized, open-label, positive controlled phase II clinical study. A total of 125 to 150 patients with renal anemia receiving regular dialysis were enrolled in this study. Those patients were randomly allocated to 5 treatment groups in a ratio of 1:1:1:1:1, with 25 to 30 patients in each group.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date August 16, 2023
Est. primary completion date March 17, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male and female patients at the age of 18~75 (including critical value). 2. Patients clinically diagnosed with renal anemia who have received dialysis for at least 12 weeks (hemodialysis=3 times/week, total urea clearance index (Kt/V) =1.2 or urea reduction rate (URR) =65%; peritoneal dialysis=4 times/day, weekly Kt/V=1.7); 3. Hb in screening period should be within the range of 100~130g/L (including both ends), and the deviation should not exceed 10g/L; 4. Iron status (TSAT =20% or SF ferritin =100µg/L) during screening. 5. Have been stably treated with short-acting EPO 1-3 times per week for at least 12 weeks before baseline; 6. Consent to use reliable contraceptive methods and no family planning from the screening period to 3 months after the last administration; 7. Voluntarily participate in the trial and sign the informed consent form. Exclusion Criteria: 1. Patients with a history of severe allergies (including drug allergies), especially allergic to erythropoietin, or to any component of the test drug (e.g. polyethylene glycol); 2. Have a history of kidney transplantation or plan to undergo kidney transplantation during the trial; 3. Have any other disease that causes chronic anemia (e.g., sickle cell anemia, myelodysplastic syndrome, hematologic malignancy, myeloma, hemolytic anemia, pure red cell aplastic anemia) or PRCA following therapy of erythropoietin protein; 4. Suffered from acute or chronic blood loss (such as gastrointestinal bleeding) or undergwent surgical procedures due to massive bleeding within 3 months before screening, or plan to have a surgery during the clinical trial (except for arteriovenous fistula or peritoneal dialysis tube adjustment); 5. Have a history of malignant tumors within the past 5 years (excluding non-melanoma skin cancer or excised carcinoma in situ); 6. Suffer from autoimmune diseases (such as rheumatoid arthritis or systemic lupus erythematosus) or diseases of endocrine system (such as poorly controlled diabetes mellitus complicated with peripheral vascular diseases, severe secondary hyperparathyroidism [parathyroid hormone > 800ng/L]); 7. Received systemic antibiotic treatment or C-reactive protein =30mg/L within 4 weeks due to severe infection before screening; 8. The following conditions occur during screening period: Hepatic dysfunction (AST or ALT>3 times ULN); Coagulation dysfunction (activated partial thrombin time > 1.5 times ULN); Folic acid or vitamin B12 deficiency (serum folic acid level <LLN, vitamin B12 <LLN); Positive for HBsAg, HBcAb, HIV-ABb, HCV-AbB or TP-Ab; 9. Suffer from severe thromboembolic disease, poorly controlled severe hypertension (SBP before dialysis > 170mmHg or DBP =100mmHg) or hypotension (SBP before dialysis <90mmHg); 10. Suffer from severe cardiovascular and cerebrovascular disease, severe or unstable coronary artery disease, heart failure (NYHA CLASS III or IV), or those who received coronary artery bypass grafting or percutaneous coronary intervention within 6 months, or those who had a history of myocardial infarction or stroke within 3 months; 11. Received androgen therapy or blood transfusion within 8 weeks before screening period; 12. Received long-acting ESAs within 3 months or HIF-PHI (e.g., rosalat) within 2 weeks before initial administration; 13. Participated in other clinical trials as a subject within 4 weeks before screening period or the duration from the last administration to enrollment was shorter than the 5 half-lives of the drug; 14. Have a history of epileptic seizures or mental illness; 15. Alcoholism, drug abuse or drug addiction 16. Pregnant or breastfeeding; 17. Investigator considers not suitable to enter this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant human erythropoietin injection
The dose of PEG-EPO (CHO cells) is converted according to the average weekly dose of short-acting EPO before randomization (4 weeks before randomization) multiplied by the corresponding conversion coefficient (low conversion coefficient is 0.004, High conversion coefficient is 0.008).
Human erythropoietin injection
Refer to the product instructions

Locations

Country Name City State
China The First Affiliated Hospitial,College of Medicine,Zhejiang University Hanzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Angde Biotech Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of mean hemoglobin compared to baseline during fixed treatment Change of mean hemoglobin (Hb) content from baseline during fixed treatment (fixed treatment:week 1 to week 6) Day1-Day42
Primary Change of mean hemoglobin during dose adjustment period Change of mean hemoglobin compared to baseline from week 13 to 18 during dose adjustment period (dose adjustment period: week 7 to week 18/week 20). Day85-Day126
Secondary Proportion of patients with hemoglobin keeping within the target range Proportion of patients with hemoglobin keeping within the target range (target range: the variation from baseline Hb is within ±10g/L, and HB is in the range of 100-130g/L) during treatment period (fixed treatment, week 13 to 18 during dose adjustment period). Day1-Day42?Day85-Day126
Secondary Reticulocyte count, Hematocrit, Erythrocyte count Changes of mean values of other evaluation indexes (including HCT, RET, RBC) between baseline and different stages of treatment (fixed treatment period, week 13 to 18 of dose adjustment period). Day1-Day42?Day85-Day126
Secondary Proportion of patients receiving red blood cell transfusion and number of transfusions during the trial. Day1-Day126/140
Secondary Number of iron deficiency, number of patients and proportion of patients with iron deficiency during the trial Iron deficiency was defined as SF=100µg/L and TSAT=20% in peritoneal dialysis subjects; SF=200µg/L and TSAT=20% in hemodialysis subjects. Day1-Day126/140
Secondary The number and proportion of patients with dose adjustments during the trial Day1-Day126/140
Secondary Anti-drug antibody The incidence of ADA and Nab 1,5, 9, 13, 17 weeks (before administration) and 28±2 days after the last administration (A2/B2group ,A1/B1 patients with intensive blood collection) or 14±2 days after the last administration (A1/B1 patients with sparse blood collection)
Secondary Adverse events Any adverse event that occurred during the clinical trials of all patients. Day1-Day126/140
Secondary Cmax Maximum observed plasma concentration of EPO. Day1-Day126/140
Secondary Tmax Time to maximum observed plasma concentration of EPO. Day1-Day126/140
Secondary AUC 0-t Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration of EPO. Day1-Day126/140
Secondary AUC 0-8 Area under the plasma concentration-time curve from time 0 to infinity. Day1-Day126/140
Secondary Emax Maximal effect concentriation Day1-Day126/140
Secondary Tmax of Emax Time to maximal effect concentriation Day1-Day126/140
Secondary AUE0-t Area under the plasma effect-concentriation curve from time 0 to the time of the last measurable concentration of EPO. Day1-Day126/140
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04925661 - HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia Phase 1
Active, not recruiting NCT03388385 - Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD Phase 4
Completed NCT05035641 - A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients Phase 2
Completed NCT02299661 - Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease Phase 1
Active, not recruiting NCT05265325 - A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis Phase 2
Completed NCT05864261 - Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers Phase 4
Active, not recruiting NCT05085275 - Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Phase 3
Completed NCT02708914 - Study to Compare the Safety and Efficacy of UB-851 and Eprex® Phase 3
Completed NCT02041208 - Variability of Hemoglobin Levels After Kidney Transplantation N/A
Not yet recruiting NCT04775615 - Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects. Phase 1
Completed NCT00298441 - Efficacy of Intravenous Iron Administration in Hemodialysis Patients Phase 4
Active, not recruiting NCT04408820 - Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
Completed NCT01543477 - Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
Completed NCT05951192 - A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease Phase 4
Completed NCT04454879 - Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients Phase 4
Recruiting NCT04360902 - Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients N/A
Not yet recruiting NCT03480178 - Renal Anemia Refractory to Erythropoietin
Completed NCT01306409 - Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA) Phase 4
Completed NCT00322413 - Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial Phase 3
Recruiting NCT05970172 - A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease Phase 3